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INTRODUCTION
For more than 40 years, radiation or chemotherapy or
both have been given in myeloablative doses to cancer
patients while their autologous hematopoietic cells were
s t o red for infusion to re s t o re bone marrow function. The
initial preclinical studies were perf o rmed in canine and
murine models [1-8]. To exploit this treatment principle to
its fullest potential, it is important to use agents (radiation,
drugs) that are associated with a steep dose-response curve
and a relatively short half-life. In addition, excellent sup-
p o rtive care measures are re q u i red to bridge the time
between high-dose therapy followed by hematopoietic cell
transplantation (HCT) and recovery of bone marrow func-
tion.
During the past 4 decades, important observations were
made in animal models; several anticancer drugs suitable for
use at high doses have been developed; a vast amount of new
knowledge concerning the safer administration of total body
i rradiation has been generated; extensive information con-
c e rning the characteristics, collection, and manipulation of
hematopoietic stem cells (HSCs) from marrow and peripheral
blood has been gained; potent antibiotics to prevent or tre a t
serious infections during the time of marrow aplasia have
become available; transfusional support, especially with
platelets, has become available; and hematopoietic gro w t h
factors to “mobilize” HSCs into the circulation and to
s h o rten the time to re c o v e ry of marrow function have been
developed. With these important support modalities, high-
dose therapy followed by autologous HCT is incre a s i n g
rapidly with more than 200,000 patients treated worldwide [9;
updated by M. M. Horowitz, MD in August 1999]. This
review highlights the major scientific developments and
accomplishments and defines the areas of successful use of
autologous HCT. Finally, we identify problem areas that
re q u i re further re s e a rch eff o rts to optimize clinical outcomes.
Patients who undergo autologous HCT proceed along a
4-step sequence: autologous cells are secured, processed, and
c ry o p re s e rved (step I); myeloablative antitumor therapy is
a d m i n i s t e red (step II); the graft is infused (step III); the
patient receives supportive care until re c o v e ry, which is fol-
lowed under certain conditions by consolidative therapy
(step IV). This review is organized following the same
sequence that a patient experiences during the clinical course
of an autologous transplantation pro c e d u re (Figure 1).
HEMATOPOIETIC CELL COLLECTION AND CELL
PROCESSING
Autologous cells for bone marrow grafts were initially
obtained by multiple needle aspirations in the operating ro o m
while the patient was under general or regional anesthesia.
During the early years of autologous HCT, patients usually
w e re treated in advanced stages of their underlying hemato-
logic malignancies [10-14]. After more than 20 years of fol-
low-up, 4 patients transplanted for non-Hodgkin’s lymphoma
(NHL) at the National Cancer Institute before 1978 are still
alive and in continued unmaintained complete re m i s s i o n .
The observations that peripheral blood samples fro m
animals and humans contain viable HSCs [15-20] subse-
quently made the clinical use of circulating HSCs for
h e m atologic reconstitution after high-dose therapy a re a l i t y
[21-23]. The potential of peripheral blood HSCs was furt h e r
enhanced by the fact that these cells could be “mobilized”
f rom the marrow into the bloodstream, where they can easily
be collected by apheresis. High doses of cyclophosphamide
(CY), growth factors (granulocyte colony stimulating factor
[G-CSF], granulocyte-macrophage colony stimulating factor
[GM-CSF], stem cell factor, or combinations of these agents
g reatly increase the number of HSCs in the peripheral blood
[24-28]. A prospective randomized trial demonstrated that
“mobilized” blood HSCs are superior to unstimulated mar-
row cells with respect to speed of engraftment, re q u i re m e n t s
for platelet transfusions, and number of days patients spend
in the hospital [29]. Growth factor–stimulated HSCs seem to
be equally potent, whether they are obtained from marro w
or from blood [30].
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2H o w e v e r, the potential presence of clonogenic tumor cells
in the cell collections might contribute to post-transplantation
relapse, re g a rdless of whether cells from marrow or peripheral
blood HSCs serve as the graft. “Mobilization” of tumor cells
along with HSCs was shown to occur after treatment with
chemotherapy and G-CSF [31]. Gene-marking studies in
patients with acute myeloid leukemia (AML) or chro n i c
myeloid leukemia (CML) supported these concerns [32,33].
T h e re f o re, the development of effective “purging” methods
was and still is a highly desirable goal. A major pre requisite for
the successful use of “purging” is the availability of techniques
that are suitable for monitoring residual malignant cells.
Many investigators have developed ingenious methods
for the detection of small quantities of abnormal cells.
These methods include cytogenetic and immunocytochemi-
cal techniques, clonogenic culture assays, and molecular
tests such as the polymerase chain reaction (PCR). Several
investigators have combined 2 or even 3 of these testing
principles. The sensitivity of these laboratory technologies
is such that 1 tumor cell can be detected in 105 to 106 total
cells [34-49]. Tumor cells of the following diseases can be
detected: acute lymphoblastic leukemia (ALL), AML, CML,
NHL, multiple myeloma (MM), breast cancer (BC), ovarian
tumors, and neuroblastoma.
N e g a t i v e Selection
Tumor cell “purging” can be accomplished with nega-
tive selection methods. Over the past 2 decades, investiga-
tors have developed and used a wide range of techniques to
remove tumor cells from the graft. These include in vitro
treatment of marrow aspirates or peripheral blood cell col-
lections with chemical agents, such as 4-hydro p e ro x y c y-
clophosphamide (4-HC) or mafosfamide, sometimes in
combination with other drugs; monoclonal antibodies
(MoAbs) with complement; MoAbs conjugated to magnetic
beads or toxins or chemotherapeutic agents; or incubation
with MoAbs and drugs [50-66]. Table 1 provides a list of
methods for “purging” tumor cells. Grafts manipulated in
this fashion have been used clinically for hematologic recon-
stitution after myeloablative therapy. The effect of “purg-
ing” to PCR negativity has been demonstrated in a clinical
trial of patients with NHL [63] (Figure 2). Post-transplanta-
tion hematologic re c o v e ry was mostly unaffected if the
grafts were “purged” immunologically. However, chemical
“purging” with 4-HC or mafosfamide often delays reconsti-
tution. The chemoprotective compound amifostine success-
fully overcame these inhibitory effects [67].
The clinical trials of grafts obtained with negative selec-
tion principles have yielded very encouraging results in
patients with AML, ALL, NHL, MM, BC, and neuro b l a s-
toma. However, prospective randomized trials confirm i n g
the superiority of the use of “purged” grafts over unmanipu-
lated grafts are not yet available. The major reason for the
lack of such information is the often technically demanding
n a t u re of the “purging” methods. Highly specialized labora-
tories are needed to provide these “purging” services, and
they are simply not available at many transplantation centers.
Po s i t i v e Selection
Positive selection of HSCs is based on the presence of
surface antigens expressed by early hematopoietic precursor
Figure 1. The treatment principle of autologous hematopoietic cell transplantation (HCT).
Table 1. Methods to Purge Tumor Cells From Marrow or Blood*
Physical separation
Size
Density
Osmotic lysis
Lectin agglutination
Hyperthermia
Pharmacologic
4-Hydroperoxycyclophosphamide
Mafosfamide
Immunologic
Uncoupled monoclonal antibodies
Complement mediated lysis
Immunomagnetic beads
Directly conjugated
Chemotherapeutic agent
Toxin
Magnetic bead
Radionuclide
*From Gribben JG. Antibody mediated purging. In: Thomas ED, Blume
KG, Forman SJ, eds. Hematopoietic Cell Transplantation. 2nd ed. Malden,
MA: Blackwell Science; 1999.
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cells or on growth characteristics of HSCs. Devices such as
columns containing antibody-coated beads or magnetic cell
sorting systems have allowed for the enrichment of CD34+
cells from large quantities of marrow aspirates or peripheral
blood collections with acceptable yields and a decrease in
tumor cell contamination [68-70]. Grafts obtained with
these selection techniques have been used successfully in
patients with hematologic malignancies [71,72]. In prospec-
tive trials, these grafts were shown to be safe and well toler-
ated and to lead to prompt and durable engraftment [73,74].
Other investigators have succeeded in isolating highly
purified HSCs from marrow of mice and humans [75,76].
Clinical studies using these very pure, tumor- c e l l – f ree pre p a-
rations were carried out in patients with MM, NHL, and BC.
The observations in patients with MM raised concern s
because of a delay of engraftment [77]. The data in patients
with NHL are still being analyzed. However, the results in
patients with stage IV BC are very encouraging with respect to
hematologic and immunologic re c o v e ry and clinical re s p o n s e
[78]. Clearly, an extension of these trials is warr a n t e d .
The incubation of HSCs from marrow and peripheral
blood collections with cytokines has allowed a limited
expansion of precursor cells under experimental and clinical
conditions [79-81].
PREPARATORY REGIMENS
Innumerable high-dose drug regimens in the setting of
autologous HCT have been designed and tested in various
trial cases [82]. Few preparatory regimens are based on dose
escalation data, and even fewer have been tested in larg e
prospective cooperative group trials. The earliest therapeu-
tic combinations have consisted of several drugs adminis-
t e red in high doses [13,14,83] or of drugs given together
with total body irradiation [84]. Alkylating drugs, several
antimetabolites, and the topoisomerase-inhibitor, etoposide,
are among the most frequently used agents [82-85]. Radio-
labeled MoAbs have been added to the standard CY/total
body irradiation regimen with promising results [86].
The choice of drugs for high-dose regimens is at least
p a rtly dependent on the nature of the underlying malig-
nancy. Intimate knowledge of toxicities of maximum toler-
ated doses of drugs is re q u i red, especially when a drug of
1 class is combined with 1 or more drugs, each of them at
maximum tolerated doses. The goal of the elimination of a
tumor often requires acceptance of some nonfatal degree of
organ toxicity. Veno-occlusive disease and pulmonary injury
are the most common serious clinical complications. On the
other hand, many of the autologous HCT pro c e d u res can
be carried out in an ambulatory setting for a large variety of
disorders. For example, the length of stay for HCT patients
at Stanford University has been decreased during the past
decade from more than 3 weeks to less than 1 week.
Several groups of investigators have pursued the con-
cept of many (2-4) high-dose treatments, each followed by
infusions of autologous HSCs. Patients treated in this fash-
ion had BC, Hodgkin’s disease (HD), NHL, MM, and other
d i s o rders. To d a y, no data support the use of a multiple
transplantation procedure, also called “tandem transplanta-
tions.” At Stanford University, we have explored 4 succes-
sive HCT pro c e d u res in 84 patients with advanced BC,
NHL, or HD and were unable to detect any advantage in
overall survival or disease-free survival compared with
results in patients of similar pretransplantation candidacy
who were treated with a single high-dose course followed by
autologous HCT. Moreover, the cost of repeated transplan-
tations was prohibitive because the supportive care measures
were always required after each treatment cycle.
INFUSION OF THE AUTOLOGOUS GRAFT
Little, if anything, has changed in the principle of autol-
ogous graft administration. Patients appear to have fewer
side effects with intravenous administration of small concen-
trated volumes of CD34+ cell preparations compared with
effects of large unmanipulated products [73].
The biologic conditions (eg, stroma cells, re c e p t o r s ,
cytokines) in the marrow environment re q u i red by stem
cells for growth and diff e rentiation have been the object of
considerable re s e a rch over the past 2 decades. It is beyond
the scope of this review to describe the exciting observ a-
tions that have been made in this area of re s e a rch (for
re v i e w, see re f e rence 87).
MANAGEMENT OF PATIENTS AFTER AUTOLOGOUS HCT
The management of patients during the early recovery
phase after autologous HCT has become fairly standardized
with respect to the use of antibiotics, transfusional support,
fluid and electrolyte replacement, and so on. Pare n t e r a l
nutrition for autologous transplant recipients is rare l y
required. Much of the support that was previously provided
on an inpatient basis has been shifted to the care in so-called
day hospitals, where patients are treated for several hours
during each of their initial days after transplantation. The
major part of their post-HCT care occurs in their homes (if
Figure 2. The disease-free survival (DFS) of patients with non-Hodgkin’s
lymphoma who were infused with autologous bone marrow with no polymer-
ized chain reaction (PCR)–detectable lymphoma cells (PCR-neg) was signifi-
cantly improved compared with those infused with a bone marrow containing
residual PCR-detectable  lymphoma (PCR-pos). All patients had PCR-
detectable lymphoma cells in the bone marrow before immunologic purging.
Reproduced with permission from the authors and the publisher. Gribben JG
et al. [63]. ABMT indicates autologous bone marrow transplantation.
4they live in close proximity to the transplantation center) or
in hotels, motels, or “transplant inns” (for those whose
re s idence is more than 50 miles away from the transplanta-
tion center). For example, since 1993 we have treated more
than 1000 patients in a bone marrow transplantation day
hospital at Stanford University. The readmission rate to the
hospital has ranged from 20% to 40%, mostly for fever dur-
ing the time of neutropenia. Although this approach would
have been unthinkable a decade ago, it is now feasible and is
associated with a high level of patient satisfaction and a man-
ageable complication rate. Obviously, skilled and competent
outpatient nursing care is a major key to success. More o v e r,
the short time between infusion of the autologous graft and
the re t u rn of marrow function (7-12 days) has greatly con-
tributed to the successful use of outpatient transplantation.
I n i t i a l l y, the post-transplantation use of growth factors
for patients who had received autologous bone marrow grafts
resulted in an abbreviated time to re c o v e ry of hematopoietic
function compared with patients who did not receive such
g rowth factor support [88-92]. However, the introduction of
chemotherapy and growth factor–“mobilized” blood HSC
grafts has shortened the neutropenic phase and reduced the
usefulness of growth factors after grafting [93].
Although treatment failures during the initial phase fol-
lowing autologous HCT occur relatively rarely (less than
5% of patients succumb during the first 2 months), death due
to the re c u rrence of the underlying malignancy is observed in
15% to 70% of patients during subsequent months or years.
The relapse rate depends on the remission status of the
patient at the time of HCT; for example, 85% of patients
with intermediate- or high-grade NHL who received a trans-
plant in first remission achieve durable responses compare d
with approximately 30% of patients who are treated after they
have suff e red 1 or more re c u rrences of their disease.
During the past decade, intense experimental and clini-
cal re s e a rch has been directed toward consolidation of the
remission after autologous HCT with cytokines (inter-
leukin-2 or interf e ron), drugs (cyclosporine to induce an
autologous graft-versus-tumor effect), MoAbs, irr a d i a t i o n ,
idiotype vaccines, or autologous cells (lymphokine-acti-
vated killer cells or cytokine-induced killer cells) that con-
fer antitumor effects [94-103]. Diseases in which such
f o rms of treatment have been explored include AML, ALL,
NHL, HD, MM, and BC. Some investigators have com-
bined 2 of these treatment methods in patients with AML,
NHL, HD, or  BC [104-107]. Some of the observ e d
responses and their durations have been very impre s s i v e ,
but the value of these methods must still stand the test of
a p p ropriately designed prospective trials.
PROGRESS IN HCT FOR SELECTED DISORDERS
Acute Myeloid Leuk e m i a
L a rge numbers of patients with AML have underg o n e
autologous HCT [108-111]. Either patients were tre a t e d
first with high-dose drug therapy to exploit in vivo “purg i n g ”
followed by HCT collection [109], or the grafts were incu-
bated with 4-HC or mafosfamide for in vitro “purg i n g ”
[108,110,111]. Clinical results were better in patients who
had favorable karyotypes at initial diagnosis than in patients
who presented with high-risk chromosomal abnorm a l i t i e s
[110-112]. Several cooperative groups have attempted to
define the role of autologous HCT for AML during first
remission [113-115]. The observations ranged from statisti-
cally superior disease-free survival after HCT [113,114] to
equivalence in outcome [115]. Table 2 lists several compara-
tive trials in patients with AML autografted in first complete
remission, comparing autologous HCT with other tre a t m e n t
modalities. In some studies, the failure of many patients to
receive the assigned treatment made the analysis by “inten-
tion to treat” highly uncertain [115]. The comparative clini-
cal studies in children and adults with AML have been
recently reviewed [116,117]. Since new techniques for graft
manipulation and myeloablation are likely to be developed
and pro g ress in the area of standard-dose chemotherapy is
also expected, the debate re g a rding the best therapy for
AML patients who do not have suitably matched allogeneic
donors can be assumed to continue into the next millennium.
Acute L y m p h o b lastic Leuk e m i a
In spite of many experimental and clinical eff o rts, the pub-
lished data of patients with ALL are much sparser than data of
patients with AML. Most re p o rted series describe encourag-
ing single-institution experiences [51,54,64,118,119]. Potent
methods to remove viable ALL cells have been developed over
the past 20 years (see previous section), but convincing larg e
p rospective trials are lacking because of their technically
demanding nature .
C h r onic Myeloid Leuk e m i a
Autologous HCT for patients with CML has been
attempted for 25 years without leading to durable re m i s-
sions [120,121]. However, a comparison of autografted
patients to a control group with similar clinical feature s
indicated that autografting confers a survival advantage even
without disappearance of the disease marker, Philadelphia
c h romosome [122]. Several methods of in vivo “purg i n g ”
with aggressive systemic chemotherapy [123] or in vitro
“purging” of the graft have been developed and have yielded
intriguing results [79,124,125], which deserve furt h e r
prospective evaluation in well-designed trials.
H o d g k i n ’ s Disease
An undisputed indication for autologous HCT is in
patients with HD who have failed first-line standard ther-
a p y. Long-term disease-free survival beyond 5 to 10 years is
attained in approximately 30% to 60% of patients [86,126-
130]. Even better results have been achieved in patients
who have poor risk features at initial presentation and who
a re transplanted early in their first partial or complete
remission [131,132]. In 2 trials, the outcome of autologous
HCT has been compared with that of standard manage-
ment of HD patients, with both studies showing a signifi-
cant disease-free survival advantage for those patients
u n d e rgoing HCT [133,134].
N o n - H o d g k i n ’ s L y m p h o m a
L a rge series of patients with NHL have been studied
over the past 2 decades [135-139]. Approximately 50% of
the patients who are in “sensitive relapse,” that is, respond-
ing to second-line therapy after a relapse to their initial
t reatment, appear to enter a prolonged second complete
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remission after myeloablative pre p a r a t o ry regimens and
autologous HCT. The advantage of HCT over standard -dose
therapy for relapsed NHL was demonstrated in a prospec-
tive randomized trial [140]. The outcome of this pivotal
study is illustrated in Figure 3. More o v e r, patients who
received transplants in first complete remission achieved sta-
tistically significant superior disease-free survival compared
with patients who received conventional therapy, as shown
in a large single-center study [141].
Multiple My e l o m a
High-dose therapy followed by autologous HCT for
M M has been explored in patients who were in various
remission stages of their disease [74,142]. This tre a t m e n t
modality has been defined in a large clinical trial in which
autologous HCT was compared prospectively with conven-
tional dose therapy and was shown to lead to statistically
significant superior disease-free survival and overall survival
[143]. However, only a small group of patients attained
durable remissions. There f o re, eff o rts have been made to
i m p rove the clinical results by optimizing the autologous
graft by tumor cell removal through positive or negative
selection [65,74,77], through intensification of therapy
[142], or by using immunotherapy with interferon [101] or
idiotype vaccines and administration of dendritic cells
[102,144,145]. The benefits conferred on survival gains and
cures by these technologies remain to be demonstrated.
B r east Cancer
Women with high-risk (stages II or III) or advanced
(stage IV) B C re p resent the largest groups of patients tre a t e d
with high-dose chemotherapy and autologous HCT [ 1 4 6 , 1 4 7 ] .
Relatively small comparative studies concerning the role of
autografting have not yielded definitive results [148,149].
A p p ropriately designed large clinical trials have been per-
f o rmed during the past decade, an adequate number of
patients have been accrued and treated, and the data should
be ready for a meaningful analysis within the next 2 years.
Other Disor d e r s
N e u roblastoma is one of the cancers in children for
which autologous HCT has resulted in significant improve-
ment of therapy leading to long-term remissions and cure
[58,150]. The use of autologous grafts devoid of tumor cells
after multimodality “purging” was found to be equivalent to
transplantation of allogeneic marrow [151].
The list of other life-threatening conditions that can be
treated successfully with high-dose therapy and autografting
includes amyloidosis [152], several autoimmune diseases
[153,154], certain brain tumors [155], and a variety of pedi-
atric cancers [156].
PROBLEM AREAS OF AUTOLOGOUS HCT
C l e a r l y, autologous HCT can re s t o re hematopoiesis
after myeloablative anticancer therapy. However, many
problems remain, as listed in Table 3.
The age limit of transplantation candidates has been
raised over time, especially with improved supportive care.
It is now clear that cancer patients in their eighth decade of
life can be considered for autologous HCT provided they
have no other serious comorbid conditions.
Table 2. Comparison of Allogeneic Bone Marrow Transplantation, Autologous Bone Marrow Transplantation, and Chemotherapy for AML in First Remission*
Study/(Date) Reference No. Treatment No. of Pts DFS P value OS P value Relapse P value
France † [162] AlloBMT 20 66% 18%
(1989) AutoBMT 12 41% <0.004 50% <0.0002
Chemotherapy 20 16% 83%
Netherlands † [163] AlloBMT 23 51% NS 66% 0.05 34% 0.03
(1990) AutoBMT 32 35% 37% 60%
Boston † [164] AlloBMT 23 62% NS 0% Significant
(1995) AutoBMT 27 62% 38%
‡ AlloBMT 31 56% NS 20% 0.04
AutoBMT 53 45% 50%
EORTC/GIMEMA ‡ [113] AlloBMT 168 55% 59% 27%
(1995) AutoBMT 128 48% Significant 56% NR 41% NR
Chemotherapy 126 30% 46% 57%
GOELAM ‡ [165] AlloBMT 88 44% 53%
(1997) AutoBMT 86 44% NS 50% NS
Chemotherapy 78 40% 55%
US Intergroup ‡ [115] AlloBMT 113 43% 46% 0.04 29%
(1998) AutoBMT 116 34% NS 43% 0.05 48%
Chemotherapy 117 34% 52% 62%
† AlloBMT 92 47% NR 45% NR
AutoBMT 63 48% 55%
MRC ‡ [114] AutoBMT 190 53% 0.04 57% 0.2 37% <0.01
(1998) Chemotherapy 191 40% 45% 58%
*AML indicates acute myeloid leukemia; AlloBMT, allogeneic bone marrow transplantation; AutoBMT, autologous bone marrow transplantation; Chemotherapy-
chemotherapy; NS, not significant; NR, not reported; DFS, disease-free survival; OS, overall survival
†Results analyzed based on actual treatment received.
‡Patients assigned to transplantation based on availability of matched siblings or to chemotherapy and analyzed on the basis of intent to treat.
6If one uses a cytotoxic drug at maximum tolerated dose,
often in combination with other agents or total body irradi-
ation, re g i m e n - related toxicity becomes obvious, especially
in the form of oropharyngeal mucositis, gastroenteritis, dif-
fuse alveolar hemorrhage, veno-occlusive disease, or other
o rgan function impairment. Such toxicity can sometimes
lead to fatal multiorgan failure syndromes. Fort u n a t e l y,
t h rough judicious use of regimens, such serious pro b l e m s
have been reduced to less than 5%, even into the 1% to 2%
range.
Graft failure leads only rarely to early or late post-trans-
plantation pancytopenia. If an adequate quantity of CD34+
cells has been cry o p re s e rved and infused, this problem occurs
most frequently in patients who develop severe viral infec-
tions with cytomegalovirus or human herpes virus type 6.
The incidence of opportunistic infections after autolo-
gous HCT is much lower than is encountered in allogeneic
HCT recipients. Occasionally, preexisting infections with
Aspergillus species are reactivated (approximately 1% of the
more than 1400 autologous HCT patients at Stanford Uni-
versity developed this serious fungal infection). The mani-
festation of cytomegalovirus disease complicates the course
of approximately 5% of autografted patients.
R e l a p s e of the underlying malignancy re p resents the
major obstacle to long-term success for many patients. In
most cases, relapse represents a failure of chemotherapy and
other anticancer measures to eliminate the cancer cells in
the patient. This problem is clearly less common if autolo-
gous HCT is perf o rmed early during the clinical course,
that is, during first complete remission in patients who have
a high risk for relapse with conventional management, as
opposed to being perf o rmed in patients who have failed
s t a n d a rd-dose therapy or have relapsed more than once
before proceeding to HCT. The answer to the relapse prob-
lem lies in appropriate patient selection, especially timing of
autologous HCT; “purging” of the graft to remove viable
tumor cells; the choice of appropriate preparatory regimens
for a given disorder; and the use of consolidative post-trans-
plantation measures, whenever feasible.
As more and more patients are living longer and being
c u red of their original malignancy, the occurrence of a sec-
ond cancer has been recognized as a serious long-term
p roblem. Whether a new tumor is a secondary event (ie,
t re a t m e n t - related) or a second event (patients with 1
tumor may be at risk for a second cancer, re g a rdless of the
t reatment modality chosen) cannot be determined. Fro m
the time of diagnosis, all therapies administered in form s
of chemotherapy or radiation at standard doses or at high
doses lead to cumulative risk. A drug such as CY infused at
a high dose over a short time period (eg, 4 g/m2 over 2 h o u r s )
may be less carcinogenic than daily use of the same amount
of this agent administered over several weeks. However,
the transplantation pro c e d u re itself is frequently incrimi-
nated as the culprit. Not dissimilar to the situation in
which the obstetrician is held responsible for every event
that occurs between the day of a child’s birth and high
school graduation, the transplant specialist is blamed for
e v e rything that happens between the day of HCT and the
p a t i e n t ’s re t i rement. It is not that simple: in a comparative
study of patients with MM who were initially treated with
s t a n d a rd doses of alkylating drugs such as melphalan or a
n i t ro s o u rea agent and then proceeded to HCT, a highly
significantly increased incidence of post-transplantation
Figure 3. Kaplan-Meier curves for event-free survival of patients with recurrent non-Hodgkin’s lymphoma in the transplantation and conventional-treatment
groups [140]. Data are based on an intention-to-treat analysis. Tick marks represent censored data. (Reproduced with permission from the authors and the pub-
lisher. Philip T, et al. [140].)
Table 3. Problem Areas of Autologous HCT*
Age limit
Regimen-related toxicity
Graft failure
Opportunistic infections
Relapse
Secondary and second malignancies
Quality of life
Cost/charges
*Probems are listed in chronologic order as they occur during the course of an
autologous transplantation procedure. The main problem is relapse of the
underlying cancer.
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myelodysplasia or AML occurred compared to what
o c c u rred in patients who were not previously exposed to
alkylating drugs [157].
Moreover, patients with HD who received an autograft
had the same incidence of hematologic malignancies as did
control HD patients who had been managed conventionally.
H o w e v e r, solid tumors were more common with grafted
compared with ungrafted patients [158]. A recent retrospec-
tive analysis of marrow and blood stem cell specimens from
12 patients who had undergone autologous HCT and subse-
quently developed a myelodysplastic syndrome revealed that
the clonal abnormality was already present in 9 patients at
the time of cell collection [159]. Malignancies after HCT
a re clearly a very serious clinical problem. Patients at risk
need to be identified as early as possible by cytogenetic or
other sensitive molecular markers [159,160], and alternative
t reatment modes such as allogeneic HCT need to be pur-
sued for those patients.
It is the goal to integrate patients as soon as possible
after autologous HCT into their personal and professional
e n v i ronment. Quality-of-life studies show that patients are
able to return to their daily lives within 6 to 12 months and
achieve a high quality of life [161]. In an ongoing evaluation
at Stanford University, autografted patients rank their qual-
ity of life on a scale of 1 to 10 (10 being the best) consis-
tently at a level of 8.9 (median).
The issue of cost and charges is loaded with economic
considerations. As it became clear that financial advantages
could be gained through the frequent use of autologous
H C T, some physicians, hospitals, and commercial enter-
prises identified this treatment modality as a suitable source
for rather generous income; thus, too many autologous
HCT procedures have been performed without defined sci-
entific goals. The criticism of autologous HCT for BC
b rought forth at the 1999 American Society of Clinical
Oncology meeting may have been partly self-inflicted. We
need to learn from our mistakes!
CONCLUDING REMARKS
What have we learned from 4 decades of experimental
and clinical research in autologous HCT?
1. Autologous HSCs can be obtained in adequate numbers
from bone marrow and peripheral blood in most trans-
plantation candidates, with blood being the pre f e rre d
source of HSCs.
2. Autologous HSCs can be “purged” of tumor cells by a
variety of methods. “Purging” techniques should be
used whenever and wherever possible, because clono-
genic tumor cells may contribute to post-transplantation
relapse of the underlying disease.
3. Cloned hematopoietic growth factors are potent agents
for the “mobilization” of HSCs, particularly if adminis-
t e red in combination with chemotherapy. However,
g rowth factors administered after transplantation of
autologous blood–derived HSCs have only a modest
effect on the speed of hematologic recovery.
4. Patients with AML may benefit from autologous HCT;
h o w e v e r, only 3 of the 7 comparative studies have
resulted in statistically superior disease-free surv i v a l
favoring autologous HCT over chemotherapy.
5 . A p p ropriately designed prospective clinical trials have
helped to define the role of autologous HCT for patients
with NHL and MM. Studies comparing HCT with stan-
d a rd-dose reinduction chemotherapy strongly favor
HCT for patients with persistent or re c u rrent HD.
6. The “hour of truth” for autologous HCT as an adjuvant
therapy for patients with stage II or III BC will be in
2001. If, at that time, the trial results are negative,
e n t i rely new concepts will need to be developed. The
recently completed studies in patients with stage IV BC
were “underpowered” and need to be redesigned.
7. One wonders why chemotherapy in standard doses and
high-dose therapy followed by HCT are considere d
competitive rather than complementary concepts. An
adversarial attitude between groups of investigators rep-
resenting diff e rent concepts interf e res with pro d u c t i v e
re s e a rch. More o v e r, the use of the lay press has never
helped in finding scientific answers.
8. M o re study discipline by all clinical investigators is
urgently required. Patients, however, can participate as
study subjects in comparative trials only if the primary
specialists enroll them at the appropriate time during
the course of their disease.
9. Valid successful re s e a rch to achieve new knowledge in
autologous HCT re q u i res a firm long-term commit-
ment to high-quality clinical investigations by third par-
ties and federal funding agencies.
1 0 . The future of autologous HCT can be exceptionally
bright, especially considering recent scientific develop-
ments, such as new knowledge in the area of drug resis-
tance, stem cell isolation, gene transfer, and post-trans-
plantation immunotherapy to overcome the problem of
relapse.
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